

ASX ANNOUNCEMENT

29 September 2026

Little Green Pharma Ltd (ASX: LGP)

CHANGE OF AUDITOR



Little Green Pharma Ltd (ASX:LGP) (**LGP** or the **Company**) advises that the Australian Securities and Investments Commission (**ASIC**) has consented to the resignation of BDO Audit Pty Ltd (**BDO**) as auditor of the Company in accordance with section 329(5) of the *Corporations Act 2001* (Cth) (**Corporations Act**). BDO's resignation took effect on 28 September 2026.

Following receipt of ASIC's consent, the Board has appointed the auditor of Cannatrek Ltd, L.S Bainbridge & Others trading as Pitcher Partners (**Pitcher Partners**), as auditor of the Company with effect from 28 September 2026, in accordance with section 327C(1) of the *Corporations Act*. Pitcher Partners has provided its written consent to act in accordance with section 328A of the *Corporations Act*.

Pursuant to section 327C(2) of the *Corporations Act*, Pitcher Partners will hold office until the Company's next Annual General Meeting, at which shareholders will be asked to approve the appointment of Pitcher Partners as auditor of the Company. Further details will be set out in the Notice of Annual General Meeting.

The Board thanks BDO for its services to the Company and looks forward to working with Pitcher Partners.

ENDS
APPROVED FOR RELEASE

A handwritten signature in black ink, appearing to read "Alistair Warren".

Alistair Warren
Company Secretary

Alistair Warren
Company Secretary
Little Green Pharma
E: cosec@lgp.global
T: +61 8 6280 0050

Paul Long
Group CEO
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company, formed through the merger of Little Green Pharma and Cannatrek to create the LGP Cannatrek Group - one of the largest pure-play medicinal cannabis companies globally, with vertically integrated operations spanning cultivation, GMP-certified manufacturing, distribution, clinics and digital health across Europe and Australia.

The Group has a diverse and growing portfolio of cannabis-based medicines with products distributed across Australia and over eleven export markets via a network of wholesalers, pharmacies, clinics and GPs.

The Group operates major production facilities in Denmark and Australia, including the largest medicinal cannabis production facility in Europe, and ranks among the leading suppliers in Australia, Germany and France, positioning it as a key player in global medicinal cannabis markets.

Following completion of the merger on 1 June 2026, Cannatrek's strong balance sheet and cash-generative Australian operations are expected to provide a platform to scale the Group's Denmark facility and accelerate its expansion into European growth markets, while leveraging vertical integration and scale to sustain and improve margins across the combined business.

For more information about the LGP Cannatrek Group go to: <https://investlittlegreenpharma.com/>

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint. To easily update your communication preferences, visit: www.investorcentre.com/au

